1038261-38-9

Usage

Uses

Used in Medicinal Chemistry:
1-(2-chlorophenyl)-1H-1,2,3-triazole-4-carboxylic acid is used as a building block for the synthesis of pharmaceuticals due to the diverse biological activities of 1,2,3-triazoles. Its carboxylic acid group allows for further modification and derivatization to develop new drug candidates or chemical probes.
Used in Drug Discovery:
1-(2-chlorophenyl)-1H-1,2,3-triazole-4-carboxylic acid is used as a valuable tool for research and drug discovery efforts, as the chlorophenyl group can potentially affect the compound's interactions with biological targets, providing insights into its potential therapeutic applications.
Used in Chemical Probe Development:
1-(2-chlorophenyl)-1H-1,2,3-triazole-4-carboxylic acid is used as a versatile compound for the development of chemical probes, thanks to its carboxylic acid group, which enables further modification and derivatization to explore its interactions with various biological targets.

Upstream product

• 3296-07-9 1-azido-2-chlorobenzene 
• 471-25-0 Propiolic acid 
• 1126635-72-0 1-(2-chlorophenyl)-1H-1,2,3-triazole-4-yl-methanol 
• 95-51-2 o-chloroaniline 

Downstream Products

• 66913-42-6 1-(2-chlorophenyl)-1H-1,2,3-triazole 

Relevant academic research and scientific papers

One-Pot Synthesis of 1-Monosubstituted 1,2,3-Triazoles from Propargyl Alcohol

A one-pot synthesis of 1-monosubstituted-1,2,3-triazoles from propargyl alcohol and various aryl azides was achieved. This simple method provides concise and efficient access to various 1-monosubstituted 1,2,3-triazole derivatives through a three-step one

Synthesis of 1,2,3-triazole hydrazide derivatives exhibiting anti-phytopathogenic activity

A series of new 1,2,3-triazole derivatives have been prepared and screened for their antifungal activity against phytopathogenic fungi using the mycelium growth inhibition method in?vitro. The results indicated that the 1,2,3-triazole hydrazide scaffold d

Discovery of a novel 6,7-disubstituted-4-(2-fluorophenoxy)quinolines bearing 1,2,3-triazole-4-carboxamide moiety as potent c-Met kinase inhibitors

A series of 6,7-disubstituted-4-(2-fluorophenoxy)quinoline derivatives possessing 1,2,3-triazole-4-carboxamide moiety were designed, synthesized and evaluated for their in vitro cytotoxic activities against four typical cancer cell lines (A549, H460, HT-29, and MKN-45). Most compounds showed moderate-to-excellent antiproliferative activity. Compounds 32, 36, 37, 45, 51, and 52 were further examined for their inhibitory activity against c-Met kinase. The promising compound 37, with a c-Met IC50 value of 2.27 nM, was identified as a multitargeted receptor tyrosine kinase inhibitor. The analysis of their structure-activity relationships indicated that compounds with EWGs, especially chloro group, at 2-position on the phenyl ring (moiety B) have potent antitumor activity.

Boronic acid catalysis for mild and selective [3+2] dipolar cycloadditions to unsaturated carboxylic acids

Herein, the concept of boronic acid catalysis (BAC) for the activation of unsaturated carboxylic acids is applied in several classic dipolar [3 + 2] cycloadditions involving azides, nitrile oxides, and nitrones as partners. These cycloadditions can be used to produce pharmaceutically interesting, small heterocyclic products, such as triazoles, isoxazoles, and isoxazolidines. These cycloadducts are formed directly and include a free carboxylic acid functionality that can be employed for fur-ther transformations, thereby avoiding prior masking or functionalization. In all cases, BAC provides faster reactions, under milder conditions, with much improved product yields and regioselectivities. In some instances, such as triazole formation from the reaction of azides with 2-alkynoic acids, catalysis with ort/io- nitrophenylboronic acid circumvents the undesirable product decarboxylation observed when using thermal activation. By using NMR spectroscopic studies, the boronic acid catalyst was shown to provide activation by a LUMO-lowering effect in the unsaturated carboxylic acid, likely via a monoacylated hemiboronic ester intermediate.